Association of treatment with nirmatrelvir and the risk of post–COVID-19 condition
About The Study: This cohort study found that in people with SARS-CoV-2 infection who had at least one risk factor for progression to severe disease, treatment with nirmatrelvir within five days of a positive SARS-CoV-2 test result was associated with reduced risk of post−COVID-19 condition (also known as long COVID) across the risk spectrum in this cohort and regardless of vaccination status and history of prior infection. The totality of the findings suggests that treatment with nirmatrelvir ...















